Business Context and Reporting Period
Pulse Biosciences, Inc. (PLSE) filed a Form 8-K on February 5, 2026, to report the release of clinical data from its nPulse Cardiac Catheter first-in-human feasibility study. The data, presented at the 31st Annual AF Symposium 2026, assesses the safety and effectiveness of the Company's nanosecond pulsed field ablation (PFA) device for treating atrial fibrillation.
Key Financial Metrics
This filing is a Current Report (Item 8.01) regarding a clinical milestone and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Findings
The primary material event is the publication of 6- and 12-month data from a study involving 165 patients treated by nine investigators in Europe. Key clinical findings include:
- Procedural Success: 96% (45/47) at one year and 100% (75/75) at 6 months for evaluable patients.
- Efficiency: Average of 16.1 applications per procedure; total procedure time averaged 65 minutes; fluoroscopy time averaged 9.8 minutes.
- Safety: A 1.3% (2/150) rate of serious adverse events (SAE) related to the primary safety endpoint.
Outlook, Risks, and Management Commentary
Management highlighted the device's unique design for circumferential ablation in a single treatment cycle. The filing incorporates a press release (Exhibit 99.1) detailing these late-breaking data points. No specific forward-looking financial guidance or new risk factors were disclosed in this specific text, though clinical development inherently carries risks regarding regulatory approval and commercialization.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed statistical analysis.
- Confirm the regulatory status of the nPulse Cardiac Catheter System in the US and Europe.
- Review the Company's most recent 10-K or 10-Q for current cash runway and burn rate, as this 8-K contains no financial data.
- Assess the timeline for potential regulatory submissions based on the reported 12-month data.